GlassScriptPhysician profile
Jason R Daughtry
NPI 1356355168
$2,664.44
in general payments reported to CMS, 2019-2025
19 companies · $548 in 2025
The $548 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $209 · 2021: $186 · 2022: $574 · 2023: $369 · 2024: $431 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.01 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $571.70 | 2020-2025 | Istent Infinite, Idosetr, Idose |
| Abbvie INC. | $354.41 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Sun Pharmaceutical Industries INC. | $295.86 | 2022-2024 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $289.22 | 2019-2023 | One Series Ultra |
| Rxsight INC | $252.74 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Biotissue Holdings INC. | $234.11 | 2022-2025 | |
| Allergan, INC. | $114.71 | 2019-2022 | |
| Alcon Vision LLC | $83.39 | 2019-2023 | Simbrinza |
| New World Medical,INC. | $78.18 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $77.87 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $55.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $54.89 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $50.93 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $41.68 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $41.56 | 2019-2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $20.20 | 2023 | Lotemax Sm, Vyzulta, Alrex |
| Aerie Pharmaceuticals, INC. | $19.41 | 2021 | |
| Thea Pharma INC. | $15.07 | 2023 | Iyuzeh |
| Shire North American Group INC | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Daughtry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.